503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Open-Science Healthcare Price Transparency Catalog · CC-BY-4.0

Losing Weight RX Open Pharmacoeconomic & Policy Datasets (2026)

Four peer-citable empirical datasets (467 audited records, 21 compiled Apache Parquet splits, and 4 permanent CERN/Zenodo academic DOIs) engineered by the Losing Weight RX Pharmacoeconomics & Consumer Audit Desk for researchers, health-policy journalists, and consumers.

Primary Empirical Rows
467
Permanent Zenodo DOIs
4 Minting IDs
HF Parquet Splits
21 Splits
Metadata Standards
Croissant 1.0
DOI: 10.5281/zenodo.24139315 · 198 Audited Rows

US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026)

Step-by-step pharmacoeconomic panel dataset tracking 198 clinical dose-escalation observations (0.25-2.4 mg semaglutide and 2.5-15.0 mg tirzepatide) across 18 US telehealth platforms and retail autoinjectors, measuring effective USD per active milligram, step-up penalties, platform membership unbundling, and 52-week cumulative patient expenditure.

DOI: 10.5281/zenodo.24139325 · 108 Audited Rows

US Commercial Insurance GLP-1 Prior-Authorization, Step-Therapy & Cash Bypass Benchmark (2026)

Structured health-policy and payer-formulary audit across 108 US commercial PBM, self-insured employer, ACA Marketplace, Medicare Part D, and direct cash-pay benchmarks evaluating GLP-1 prior-authorization BMI gates, step-therapy durations, lifestyle-app locks, and Q1 deductible out-of-pocket exposure.

DOI: 10.5281/zenodo.24139333 · 110 Audited Rows

Parenteral vs. Sublingual vs. Retail IV Lounge Bioavailability & Cost Index (2026)

Comparative pharmacokinetic and consumer expenditure dataset (110 observations) benchmarking systemic bioavailability percentages, monthly absorbed active milligram yield, and 12-month all-in patient costs across at-home 503A subcutaneous injections, sublingual dissolving tablets, retail IV drip lounges, and oral capsules.

DOI: 10.5281/zenodo.24139340 · 51 Audited Rows

US 50-State + DC Telehealth Modality, Medicaid GLP-1 Coverage & Local Clinic Cost Matrix (2026)

51-jurisdiction US regulatory and geographic price-disparity matrix (50 states plus Washington, DC) indexing state telehealth modality rules (asynchronous vs synchronous video), Medicaid adult obesity GLP-1 coverage, state-employee plan formulary status, non-resident 503A board tiers, and local brick-and-mortar medspa vs online flat-rate savings.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Losing Weight RX Open Pharmacoeconomic & Policy Datasets (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  2. Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025). Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA health forum, 6(3), e245586. https://doi.org/10.1001/jamahealthforum.2024.5586
  3. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  4. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wang, S., Fan, D., Yao, Q., & Sun, X. (2025). The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China. Diabetes, obesity & metabolism, 27(9), 5269-5279. https://doi.org/10.1111/dom.16580